RTW Investments L.P. — 2023 Investments
1 investments dated 2023 · listed companies and verified rows first · show all
Lenzlenz-tx.comin𝕏Mar 2023 · $83.5M
LENZ Therapeutics is a pharmaceutical company developing and commercializing VIZZ™, an FDA-approved aceclidine-based eye drop for treating presbyopia, a vision condition affecting over 128 million people in the US.
BiotechHealthtechMedical DevicesSan Diego, US
James McCollum(Co-founder, Board Member)Eef SchimmelpenninkinEvert Schimmelpennink(President and CEO)
Co-investorsAlpha Wave GlobalRA CapitalRaptor GroupSectoral Asset ManagementVersant Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.